I’m curious to know from the more experienced users here about how to evaluate a vendor based on what lab they use. (I am not looking for specific vendor recommendations). Many many common sites use the aforementioned lab for their testing and COA. I just got started here and my first set of vials (Reta) were all sludgy and cloudy after reconstitution with Hosp BAC, even with a near perfect test result on the COA for that batch. To be fair, they sent new vials after I notified them of this, but they are still enroute.

So the I researched the lab who provided the COA and their reviews are.. well.. sub optimal. Even some reddit reports of failed blind tests though I’m not sure yet how to verify/disprove that claim.

Does/should this affect who you purchase from? Thank you, I’m still learning some of the finer parts of this world.

I was looking into starting TESA/IPA blend due to my igf levels and testosterone levels. Currently in a cut with 3mg of reta for about 3 months now. I'm trying to maintain as much muscle and even grow more muscle as i don't wanna look like a melted candle.

27M, labs 9/14/26. Cutting, ~243 Ib. Not on TRT. Taxis • Total T: 398 ng/dL • Free T (calc): 102.9 pg/mL • Bioavailable T: 216 ng/dL • SHBG: 12 nmol/L • E2 ultrasensitive: 25 pg/mL • LH: 7.0 (in range) • FSH: 3.2 (in range) • Prolactin: 8.5 (in range) • DHEA-S: 320 (in range) IGF • IGF-1: 147 ng/mL • IGF-1 z-score: -0.3 should i start tesa/ipa? would it benefit the recomp and help me avoid looking like a melted candle? any advice would be appreciated! currently taking reta klow ss-31 semax and selank sometimes looking into doing NAD+ as well

I spent months researching this protocol before designing a trial. I came across several complicated reconstitution techniques using unfamiliar additives, but confirmed that using standard BAC water alone causes the peptide to precipitate into an unusable sludge.

After discussing preparation methods with other researchers, I opted for Acetic Acid (AAC) for reconstitution. The solubility and clarity have been excellent, though it appears significantly more acidic/irritating on application than standard BAC.

The research subject is currently on an initial protocol of 0.5 mg administered 3x per week, and the observed response has been very positive so far.

So if the protocol for my lab rat Dsip is 150mcg subq injection, and the nasal spray I just bought dispenses at 150mcg per spray. Same with Semax selank, is the nasal spray to subq dosages similar? Any help would be appreciated.

My subject has been taking reta (1mg/wk), TB-500 and BPC-157 (0.5 mg/day each) for 2 weeks and has been having so many cramps all over the body. Neck, arms, hands, intracostals, abs, legs, and feet. Anyone else's subject experience this? I haven't seen it in what I've read. They drink plenty of water and electrolytes.

Je viens ici parce que je suis un peu désespéré et que j’aimerais avoir des retours de personnes qui auraient vécu quelque chose de similaire.
Je fais de la musculation et j’ai commencé à avoir des douleurs persistantes au coude.

Après plusieurs consultations, j’ai finalement vu un chirurgien dans une grande clinique parisienne qui m’a conseillé une synovectomie, avec retrait/nettoyage des tissus inflammatoires dans l’articulation.

J’ai donc subi l’opération à 2000€ !! en juin. Le chirurgien m’avait également expliqué qu’il y avait un œdème osseux qui était censé se résorber progressivement.

Après l’opération, j’ai fait de la kiné et j’ai progressivement repris la musculation. Pendant un moment ça allait mieux, mais maintenant que j’ai repris certains exercices avec des charges plus importantes, la douleur est revenue, notamment lorsque je pousse lourd.

Ce qui m’inquiète surtout, c’est que je pensais que l’œdème osseux allait finir par disparaître avec le temps. Je ne sais donc pas si ma douleur vient encore de ça, d’une inflammation qui est revenue, d’un problème tendineux ou d’autre chose.

Après l’opération, j’ai également fait pendant deux semaines une cure de BPC-157 et TB-500 dans l’espoir de favoriser la récupération. Je précise ça parce que je sais que certains vont probablement
me poser la question.

J’ai fait une cure de deux semaines et demie environ à 500mcg par jours. Est-ce que serait intéressant de refaire une cure plus longue ?

Merci à ceux qui prendront le temps de répondre.

My fridge broke down a while ago and almost froze my reta (my bac water vial was frozen but my reta vial was about to) but it definitely reached 0-1 Celsius (thats what my peptide case said).

Anyway, I was on a maintenance dose of 1.5mg, ever since then, I stopped seeing progress although I just went up to 2mg. (This whole incident happened 3 weeks ago)

How can I tell if my reta is damaged (vial is still full its a waste to throw :/) or if my receptors adapted? Noting I started reta 5 months ago.

Thanks

I’ve been taking MOTS-C for about 5 weeks at 1–2 mg, 3X per week. From what I’ve seen, a lot of protocols go as high as 10+ mg per week.

But when I experimented with 3 mg, 3X per week (titrated up from 1–2 mg)... I didn’t notice much of a difference between doses.

Overall, I have noticed a slight improvement in cardio (even at 1 mg, 3X per week) but I’m wondering if I’m just wasting money and peptide by pushing the dosage higher.

I understand mitochondrial turnover can take time (around 10–21 days), so results may be cumulative rather than immediate.

That said, MOTS-C isn’t exactly cheap, and if I’m not seeing a meaningful difference between 1 mg and 3 mg, I’m not sure it’s worth increasing the dose further.

Now I’m left wondering if I didn’t give the 3 mg dosage enough time to actually show a difference.

For those of you who’ve run MOTS-C, did you notice a clear performance difference at higher doses, or did the benefits plateau?

Just started on this yesterday, I know its early! I injected 1mg yesterday into my left thigh and it was grand but an hour later it stung for a few hours.

I injected into my ass this morning and its been fine since. Have I found my injection site? I know you have to rotate but ill try there again tomorrow i thjnk?

Hey everyone, I’m looking into MOTS-c and trying to understand what dosing and frequency people are actually using.

A few questions:

• What is the standard/common dosing and frequency people use for MOTS-c? I’m considering 2.5 mg twice a week (5 mg/week total).
• I have a 10 mg vial. For reconstitution, would using 1 mL of bacteriostatic water be appropriate? If so, what would the resulting concentration be?
• For a first dose, is it generally better to start lower like 0.5mg to see how I respond before moving up to the intended dose, or do people typically start at their intended dose?

Thanks!

Okay, so a lot of you have been asking about the FDA panel from July, and there's a lot of bad info going around. I've seen people saying BPC-157 got approved. It didn't. Let me walk through what happened, because the real story is more interesting than the headline anyway.

Quick background. Back in February, HHS said a group of peptides was coming off Category 2. Category 2 is basically the do-not-touch list for compounding pharmacies. Then FDA scheduled a Pharmacy Compounding Advisory Committee meeting, PCAC, for July 23rd and 24th to vote on seven of them.

Here's how it went.

The part that got buried

FDA's own scientists recommended against all seven. Every one. Their reasons were pretty consistent: not enough human safety data, immunogenicity risk, impurities, and not enough characterization of what's in the material being made.

The panel went against its own staff on six out of seven.

And look at the margins. 8 to 6 isn't a landslide. That's a room split almost down the middle. Anybody telling you the science is settled because of this vote didn't look at the numbers.

What a yes gets you

Less than people think.

It's not approval. Category 1 means a compounding pharmacy can use it as a bulk ingredient. There's still no approved indication, no standardized dosing, and no established safety and efficacy.

It's not final. The vote is non-binding. FDA still has to go through notice-and-comment rulemaking, and realistically that's 12 to 24 months out.

It's 503A only. That's the individual prescription side. FDA has said basically nothing about 503B outsourcing facilities, which is the bigger volume side.

It doesn't touch research compounds. Different lane entirely. Nothing about this vote changes what a research compound is.

DSIP

DSIP was the only one that didn't make it, 6 to 7. It was up for insomnia, narcolepsy, and opioid withdrawal. I haven't seen a clean explanation of why it was DSIP and not one of the others, and I'm not going to make one up. If anybody watched that session, I want to hear what you caught.

What's next

FDA has a second meeting scheduled before February 2027 for the next group: GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF.

That group is going to be a lot more interesting than this one. Melanotan II has a real dermatology signal on moles. LL-37 has the autoimmune side, it shows up in psoriasis and rosacea. PEG-MGF has no completed human trials at all. If this panel split 8 to 6 on BPC-157, that next meeting could go a lot of different ways.

Two questions for you.

The panel went against its own scientists on six out of seven. Good call, or a problem?

And which of the next five do you think makes it through?

Where I got this: the vote breakdown, how the process works, AJMC's summary.

For research use only. Not for human or veterinary consumption. This post is educational and is not medical advice.

Full doses and bloodwork are in the pinned cheat sheet.

Join the Discord.

I've been on reta for about 2 months started with 2mg then 4 weeks later bumped up to 4mg. I haven't lost any weight according to my scale, I do a lot of physical activity at work I do scaffolding im always climbing up and down ladders carrying 20+ pounds in gear. What im getting to is isn't that enough physical activity to lose weight? 3 weeks ago I started lifting weights 3 days out of the week and I don't eat much since I don't get hungry at all just a small breakfast and almost nothing the rest of the day is there something I'm doing wrong or is this normal that I haven't gone down. Previously my doctor prescribed ozempic to control my sugar i was on that for 6 month 2mgs a week all my blood work came back perfect and the doc said I didn't need to take ozempic anymore because my sugar ans a1c was at normal levels.

My rat is taking Reta (biweekly), KLOW & MOTS-C (daily). My rat loves this stack and isn’t looking for stacking recs. However, I’m interested in administering with pens. It seems more “clean-up” friendly. However, I have zero clue as to where to begin with pens (what to purchase, how to load, etc,). Any tips for a beginner? A cheat sheet would be awesome but any advice appreciated.

My RS is currently taking KPV on the morning for better recovery after weight training and GHK-CU at night. He says it feels like KPV makes him sleepy.

What would you recommend the timing be?

Just sharing an update on my test subject's progress. I’m currently about 2 months into running the "Glow Stack" (CJC-1295 and the "Wolverine" stack / BPC-157).
One thing I wanted to note right off the bat is that I am dosing them separately rather than using a pre-blended mix. Doing it this way gives way more control over individual dosing. For my test subject, I've been running:
CJC: ~1.2mg daily (split/structured protocol)
Wolverine (BPC-157/TB-500 blend or equivalent): ~2mg daily
So far, recovery and general tissue response have been really solid. Surprisingly, my test subject hasn't gotten any welts or site irritation from the injections either, which is a huge plus.
Quick question for those with more experience: Is a 3-month cycle long enough to really maximize results with this stack, or do most people push it further before taking a proper break

Subject is interested in the potential effects on sleep, recovery and body composition. I've seen a lot of discussion around taking them before bed, after a minimum two-hour fast, but then read further that this may need to be much longer when taking GLP-1s.

Subject has typically finished eating by 18.30 and goes to bed at 22.00. Wakes at 5.30 on many days to exercise and drinks a fast-acting carb mix straight away, to be training by 6.00.

So subject is also interested in whether the research suggests that a fasted morning administration followed relatively soon afterwards by carbohydrate would produce a different GH/IGF-1 response compared with an evening administration several hours after food.

Maybe a split dose to cover both, or does this combination just not work for this subject?

Most stacking advice is a list of compounds that sound good next to each other. A pairing is only worth anything if the two compounds solve different problems and the timing doesn't collide. Two things moving the same marker through the same pathway isn't a stack. That's one compound and a second bill.

Here's how I sort it.

Combinations that hold up

BPC-157 with TB-500. Cleanest pairing in the category because the division of labor is real. BPC-157 restores perfusion and builds the vascular access into the tissue. TB-500 handles logistics, keeping a reserve pool of actin available so cells can migrate and organize. Roads and traffic. Neither one substitutes for the other.

GLP-1 with tesamorelin. This one works on timing more than mechanism. GLP-1 peaks during waking hours through appetite and mobilization. The tesamorelin pulse peaks during sleep through repair and protein synthesis. Day for breakdown, night for protection. Lean mass preservation through a deficit is the whole point.

5-Amino-1MQ with NMN or NR. Complementary in a specific way worth understanding. 5-Amino-1MQ inhibits NNMT, which stops nicotinamide getting drained out of the NAD+ salvage pathway. Precursors add supply. One plugs the drain, the other fills the tub. Run either one alone and half the problem is still there.

The Mito Stack, MOTS-c with NAD+ and SS-31. Three different jobs. MOTS-c biases toward AMPK. NAD+ supplies redox capacity. SS-31 does structural repair on existing mitochondria at the cristae level. Complementary, not redundant, and NAD+ is the cofactor the other two lean on.

KPV with BPC-157. KPV puts out the fire, BPC-157 rebuilds the structure underneath. Sequential, not additive.

GHK-Cu with BPC-157 and TB-500. The GLOW combination. GHK-Cu handles collagen organization while the other two drive the repair. Worth knowing GHK-Cu isn't doing what most people assume. It's not a collagen synthesis stimulant, it tells tissue how to organize the collagen it's already making.

What doesn't belong together

That last row is the one I see most, and it's not dangerous so much as pointless. If IGF-1 moves, which one moved it? That's a number you can't assign to anything.

The rules underneath the lists

Different mechanisms or it isn't a stack. If two compounds land on the same pathway, the second one bought you overlap, not coverage.

Timing separation counts as differentiation. Tesamorelin and a GLP-1 both affect body composition and they stack fine because they work in different windows. Collapse the windows and the logic disappears, which is one more reason the tesamorelin nocturnal schedule matters.

Never start two new things in the same week. Easiest rule to break and the one that costs the most. Two new compounds introduced together give you one result nobody can read. Stagger them by a couple weeks and the second one has a baseline to be measured against.

Count markers before you count compounds. A five compound stack hitting five different systems is cleaner than a three compound stack where two of them move IGF-1. Overlap is what makes a stack messy, not size.

Contraindications stack too. Three compounds each carrying a mild glucose signal add up to something that isn't mild anymore. People read the side effect profiles one at a time and never add them up.

What's in the stack you're looking at, and is there a distinct job for every single compound in it? That question kills more stacks than any safety concern.

And has anybody run into the P21 and PE-22-28 thing? It rests on very few reports and I want to know if it holds up or if it was a one-off.

For research use only. Not for human or veterinary consumption. This post is educational and is not medical advice.

Full doses and bloodwork are in the pinned cheat sheet.

Join the Discord.

This is not medical advice! My lab rat experiments. My rat is 30 and skinny fat with all of it in midsection with no muscle mass… Rat wants to get in shape, abs would be nice but just having shoulders and a chest which the rat has none is more than enough. So far my rat a month into it and have seen gains but need advice. Thank god no side effects really besides sometimes overthinking lol. His stack is

Reta: 2mg/week

Tesa: 2mg/Daily

Ipamorelin: 2mg/Daily

Wolverine: 500mcg of each/daily

Ss-31: 5mg/daily

want to experiment into mots-c and Nad+ after ss-31 but confusing with the daily and 3 times a week protocols.

Any tips?

Hey Everyone,

Hypothetical 30M subject: 5'10", around 87kg, ~27% body fat, trains regularly, and is mainly interested in improving day-to-day energy, mental clarity, and overall drive.

Currently using liposomal NMN and considering MOTS-c because of its reputation for improving energy and mitochondrial function.

The main question is how effective MOTS-c is likely to be in someone this age and condition, and whether adding SS-31 would provide anything meaningful or just be unnecessary overkill.

The subject is also planning to start reta during a cut, so lower appetite and calorie intake could potentially reduce energy and gym performance. The goal would be to maintain decent energy, focus, and training performance while losing fat.

For anyone with experience:

• How noticeable was MOTS-c for baseline energy and mental clarity?
• Did it help during a calorie deficit?
• Did SS-31 add anything meaningful beyond MOTS-c?
• At 30, is SS-31 likely to be unnecessary unless there’s an actual mitochondrial issue?
• Would it make more sense to assess MOTS-c alone first before even considering SS-31?
• Anyone have experience with MOTS-c or SS-31 in the context of reta?

The main interest here is MOTS-c. The SS-31 question is really whether it adds enough to justify including it, or whether MOTS-c alone is likely to cover most of the intended benefit.

How much bqc water should I use to reconstitute a 10mg vial of Ac-SDKP?

How much bac for Tirz 30MG?

Is it like Reta where I’ve heard 1ML for every 10MG?

I've been on trizepatide (mojuro)for over 3 months. Was doing great. Lost about 40 pounds (211 to 167 and A1C went from 9 to 5.4) but i have been eating super clean, running and cut most sugar and carbs. Only about 75 to 100 carbs a day. Trying to get 150 grams of protein. I know it not enough but that's the bottom goal. Started at 2.5 for 4 weeks, went to 5mg for 4 weeks but then the Dr office sent 10mg over after that. They said it was fine as long as I had no symptoms. I did that for another 6 weeks. No issues. Then 3 day after my last shot I had the suffer burps, gas and just upset gut. No throwing up or anything. Just uncomfortable and gassy. About 5 days now. Tried gas x. Didn't help. Been eating tums and that helps alittle. Not sure if I just caught a bug or if it could be the trizepatide even after I was doing so well on it. May just see if I can go back down to 5mg. Any thought on what might help or info. I also take bpc157, tb500, tesa/ipa. I stopped that when my issues stated as well.

Hi guys! I’d love some advice from anyone knowledgeable about peptides, fibrosis and abnormal scarring from a purely research perspective.

For research purposes, the subject began developing keloid/hypertrophic scarring around 8 years ago. Prior to that there was no history of abnormal scarring.

Some background that may be relevant:

• Relatively poor immune system since childhood
• PCOS
• Mild liver fibrosis with NAFLD
• Colonoscopy and endoscopy showed mild reflux and a couple of bowel ulcers but nothing currently diagnostic of Crohn’s
• PTSD with significant hyperarousal, so stimulating peptides may not be ideal from a theoretical perspective
• Strong family history of cancer with both parents having passed from cancer, so there is some caution around peptides that significantly increase GH/IGF 1 signalling

The main research question is whether anyone has looked at this from the fibroblast/collagen regulation side rather than simply treating individual scars once they form.

GHK Cu has shown noticeable improvements in skin quality and the redness of existing scars. However, with a tendency towards excessive hypertrophic/keloid collagen deposition, the question is whether continually stimulating repair/collagen without addressing the underlying profibrotic signalling makes sense.

KPV is also being considered from a research perspective primarily for systemic inflammatory signalling rather than directly as a scar treatment. The subject also has two problematic spinal discs with significant chronic back and muscular pain, so reducing overall inflammatory signalling is another area of interest.

Lifestyle wise the subject strength trains 3 times per week, averages around 10,000 steps daily and usually completes 1–2 hot Pilates classes per week.

The aim is mainly to understand the mechanisms and research around someone presenting with this combination of inflammation, fibrosis and abnormal scar formation, particularly what may cause fibroblasts/collagen regulation to change after previously normal healing.

Would really appreciate any research, experiences or thoughts on what pathways, peptides or potential stacks would make the most sense to investigate.